NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Passage Bio, Inc. (PASG) Stock Analysis

Passage Bio, Inc. (PASG) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PASG

$4.65

−$0.10 (−2.11%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PASG with… →

PASG Key Statistics

As of Sep 4, 2026
Trading
Open
$4.63
Previous Close
$4.75
Day's Range
4.63–4.88
52-Week Range
3.29–20.00
Volume
3.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.43
Valuation
Market Cap
$14.96M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−11.08
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$45.52M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.22M
1-Year Return
−33.57%
Dividend and dates
Avg Volume
66.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PASG Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−60.59%
2025+4.06%
2024−43.86%
2023−26.81%
2022−78.27%
2021−75.17%
2020 (partial year)+15.18%

As of September 4, 2026.

PASG Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$45.52M—
2024$0.00−$64.77M—
2023$0.00−$102.06M—
2022$0.00−$136.13M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$43.15M−$45.52M—
2024$0.00—−$65.17M−$64.77M—
2023$0.00—−$103.00M−$102.06M—
2022$0.00—−$135.39M−$136.13M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PASG Valuation vs Biotechnology Median

Median of 656 stocks
MetricPASGBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Passage Bio, Inc. (PASG) is capitalised at $14.96M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 24 employees.

Over the past 52 weeks the price has ranged from $3.29 to $20.00. The most recent close on file for PASG is $4.65, dated September 4, 2026. That is −$0.10 (−2.11%) against the previous close. The latest close sits 41.34% above that 52-week low.

Financial Health

In fiscal 2025, Passage Bio, Inc. reported revenue of $0.00. The same year closed with a net loss of $45.52M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −11.08.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is 1.43. Annualized volatility over the trailing 6 years is 97.26%. The trailing one-year price return is −33.57%. Measured over 5 years, that is −54.15% a year compounded.

Growth & Income

No dividend is on file for PASG.

2026 is still running; the price is −60.59% year to date. The strongest complete calendar year on file is 2025 at +4.06%; the weakest is 2022 at −78.27%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

Passage Bio, Inc. (PASG) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Passage Bio, Inc. PASG $14.96M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Passage Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Passage Bio, Inc.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Visit website →